Skip to main content

Advertisement

Log in

Assessment of semaphorin 3A and semaphorin 7A levels in primary Sjogren's syndrome

  • Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Sjogren's syndrome (SS) is a chronic autoimmune connective tissue disease. Varying rates of system involvements may be seen in the course of the disease. Semaphorins has multifunctions in several physiological and pathological processes such as immune system regulation. The association of Semaphorin 3A (Sema3A) and Semaphorin 7A (Sema7A), which are immune semaphorins, with autoimmune diseases is interesting for researchers. We aimed to compare serum Sema3A and Sema7A levels between primary SS and control subjects, and investigated Sema3A and Sema7A levels in disease subgroups and associated system involvements. 50 consecutive primary SS patients and 40 healthy subjects followed in the Rheumatology clinic of Cumhuriyet University Medical Faculty between 2017 and 2018 were included in the study. Inclusion criteria of patients were diagnosis of primary SS according to the 2016 ACR/EULAR classification criteria. Serum Sema3A and Sema7A levels were measured by commercial ELISA kit. Both groups were similar in terms of age, gender, and body mass index. Serum Sema3A and Sema7A levels were significantly lower in SS than in the controls (p = 0.001 and p = 0.005, respectively). Serum Sema3A levels were significantly lower in patients with renal involvement than in patients without (p = 0.03). Sema3A and Sema7A may play a role in the etiopathogenesis of SS and may be a potential serological marker for the diagnosis of SS and may be a target for treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

All data have been included into the manuscript.

References

  1. Negrini S, Emmi G, Greco M et al (2022) Sjögren’s syndrome: a systemic autoimmune disease. Clin Exp Med 22:9–25. https://doi.org/10.1007/s10238-021-00728-6

    Article  CAS  PubMed  Google Scholar 

  2. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM (2010) Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun 34:400–407. https://doi.org/10.1016/j.jaut.2009.10.004

    Article  CAS  PubMed  Google Scholar 

  3. Brito-Zeron P, Baldini C, Bootsma H et al (2016) Sjögren syndrome. Nat Rev Dis Prim 2:16047. https://doi.org/10.1038/nrdp.2016.47

    Article  PubMed  Google Scholar 

  4. Callegher SZ, Giovannini I, Zenz S et al (2022) Sjögren syndrome: looking forward to the future. Ther Adv Musculoskelet Dis. https://doi.org/10.1177/1759720X221100295

    Article  Google Scholar 

  5. Ferro F, Vagelli R, Bruni C et al (2016) One year in review 2016: Sjögren’s syndrome. Clin Exp Rheumatol 34:161–171

    PubMed  Google Scholar 

  6. Stojan G, Baer AN, Danoff SK (2013) Pulmonary manifestations of Sjögren’s syndrome. Curr Allergy Asthma Rep 13:354–360. https://doi.org/10.1007/s11882-013-0357-9

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tobn GJ, Pers JO, Devauchelle-Pensec V, Youinou P (2012) Neurological disorders in primary Sjögren’s syndrome. Autoimmune Dis 2012:645967. https://doi.org/10.1155/2012/645967

    Article  Google Scholar 

  8. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88:284–293. https://doi.org/10.1097/MD.0b013e3181b76ab5

    Article  PubMed  Google Scholar 

  9. Popov Y, Salomon-Escoto K (2018) Gastrointestinal and hepatic disease in Sjogren syndrome. Rheum Dis Clin North Am 44:143–151. https://doi.org/10.1016/j.rdc.2017.09.010

    Article  PubMed  Google Scholar 

  10. Baldini C, Pepe P, Quartuccio L et al (2014) Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 53:839–844. https://doi.org/10.1093/rheumatology/ket427

    Article  PubMed  Google Scholar 

  11. Yazdani U, Terman JR (2006) The semaphorins. Genome Biol 7:211. https://doi.org/10.1186/gb-2006-7-3-211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Suzuki K, Kumanogoh A, Kikutani H (2008) Semaphorins and their receptors in immune cell interactions. Nat Immunol 9:17–23. https://doi.org/10.1038/ni1553

    Article  CAS  PubMed  Google Scholar 

  13. Lepelletier Y, Moura IC, Hadj-Slimane R et al (2006) Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol 36:1782–1793. https://doi.org/10.1002/eji.200535601

    Article  CAS  PubMed  Google Scholar 

  14. Rezaeepoor M, Shapoori S, Ganjalikhani-hakemi M et al (2017) Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients. Gene 610:59–63. https://doi.org/10.1016/j.gene.2017.02.013

    Article  CAS  PubMed  Google Scholar 

  15. Rimar D, Nov Y, Rosner I et al (2015) Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatol Int 35:1625–1630. https://doi.org/10.1007/s00296-015-3269-2

    Article  CAS  PubMed  Google Scholar 

  16. Vadasz Z, Toubi E (2012) Semaphorin 3A – a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. Lupus 21:1266–1270. https://doi.org/10.1177/0961203312456753

    Article  CAS  PubMed  Google Scholar 

  17. Vadasz Z, Haj T, Halasz K et al (2012) Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res Ther 14:146

    Article  Google Scholar 

  18. Takagawa S, Nakamura F, Kumagai K et al (2013) Decreased Semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis. BMC Musculoskelet Disord 14:40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Liao HT, Lin YF, Chou CT, Tsai CY (2019) Semaphorin 3A in ankylosing spondylitis. J Microbiol Immunol Infect 52:151–157. https://doi.org/10.1016/j.jmii.2017.07.001

    Article  CAS  PubMed  Google Scholar 

  20. Suzuki K, Okuno T, Yamamoto M et al (2007) Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature 446:680–684. https://doi.org/10.1038/nature05652

    Article  CAS  PubMed  Google Scholar 

  21. Wang P, Mao YM, Liu LN et al (2020) Decreased expression of semaphorin 3A and semaphorin 7A levels and ıts association with systemic lupus erythematosus. Immunol Invest 49:69–80. https://doi.org/10.1080/08820139.2019.1649280

    Article  CAS  PubMed  Google Scholar 

  22. Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology ınvolving three ınternational patient cohorts. Arthritis Rheumatol 69:35–45. https://doi.org/10.1002/art.39859

    Article  PubMed  Google Scholar 

  23. Ramos-Casals M, Font J (2005) Primary Sjögren’s syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 44:1354–1367. https://doi.org/10.1093/rheumatology/keh714

    Article  CAS  PubMed  Google Scholar 

  24. Yoshida Y, Kang S, Morishima A et al (2013) AB0114 semaphorin3a and semaphorin4d in rheumatoid arthritis. Ann Rheum Dis 72:A820.2. https://doi.org/10.1136/annrheumdis-2013-eular.2437

    Article  Google Scholar 

  25. Daoussis D, Melissaropoulos K, Sakellaropoulos G et al (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46:625–631. https://doi.org/10.1016/j.semarthrit.2016.10.003

    Article  CAS  PubMed  Google Scholar 

  26. Holmes S, Downs AM, Fosberry A et al (2002) Sema7A is a potent monocyte stimulator. Scand J Immunol 56:270–275. https://doi.org/10.1046/j.1365-3083.2002.01129.x

    Article  CAS  PubMed  Google Scholar 

  27. Xie J, Wang H (2017) Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis. Arthritis Res Ther 19:10. https://doi.org/10.1186/s13075-016-1217-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Aiyegbusi O, McGregor L, McGeoch L et al (2021) Renal disease in primary Sjögren’s syndrome. Rheumatol Ther 8:63–80. https://doi.org/10.1007/s40744-020-00264-x

    Article  PubMed  Google Scholar 

  29. Evans R, Zdebik A, Ciurtin C, Walsh SB (2015) Renal involvement in primary Sjögren’s syndrome. Rheumatol (United Kingdom) 54:1541–1548. https://doi.org/10.1093/rheumatology/kev223

    Article  CAS  Google Scholar 

  30. Ramos-Casals M, Brito-Zeron P, Solans R et al (2014) Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 53:321–331. https://doi.org/10.1093/rheumatology/ket349

    Article  PubMed  Google Scholar 

  31. Abrol E, Gonzalez-Pulido C, Praena-Fernandez JM, Isenberg DA (2014) A retrospective study of long-term outcomes in 152 patients with primary Sjogren’s syndrome: 25-year experience. Clin Med 14:157–164. https://doi.org/10.7861/clinmedicine.14-2-157

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

EU performed the design of the study, data collection and interpretation, and all statistical analysis and ACU contributed. HOD performed biochemical analyses of the study. AS checked the final version of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ali Sahin.

Ethics declarations

Conflict of interest

There is no conflict of interest.

Ethical approval

The study approval was obtained from the ethics committee of Cumhuriyet University Medical Faculty (date: 11th July 2017, approval number: 2017-07/08).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Urhan, E., Urhan, A.C., Dogan, H.O. et al. Assessment of semaphorin 3A and semaphorin 7A levels in primary Sjogren's syndrome. Rheumatol Int 43, 1087–1092 (2023). https://doi.org/10.1007/s00296-022-05197-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-022-05197-y

Keywords

Navigation